Novartis sees off ICC claim over pain relief drug

A US subsidiary of Swiss pharmaceuticals group Novartis has defeated a US$82 million ICC claim brought by a former Japanese partner over its decision to discontinue development of a pain relief drug.

Unlock unlimited access to all Global Arbitration Review content